KneeT-vegan: The Effect of a 2-week Preoperative Vegan Diet Versus Omnivorous Diet on the Protein Turnover in the Osteoarthritic Knee

Sponsor
Wageningen University (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT06130956
Collaborator
Gelderse Vallei Hospital (Other), Rijnstate Hospital (Other)
40
2
12

Study Details

Study Description

Brief Summary

Rationale: Protein from plant-based foods may be unable to stimulate protein synthesis due to a suboptimal essential amino acid content and a lower digestibility. However, a more optimal amino acid profile may be achieved by increasing portions sizes and blending multiple plant-based sources. Studies investigating the anabolic properties of vegan diets (total elimination of animal-based foods) rather than single plant-based foods in older adults are scarce. It remains unknown if a vegan diet can also affect protein synthesis rates in other musculoskeletal tissues than muscle.

Primary objective: To assess the effects of a 2-week preoperative vegan diet in comparison to an omnivorous diet on protein synthesis rates in Hoffa's fat pad, synovium, tendon, bone, ligaments, menisci, and cartilage in older adults with knee osteoarthritis undergoing total knee arthroplasty.

Secondary objective: To assess the effects of a 2-week preoperative vegan diet in comparison to an omnivorous diet on blood pressure and plasma amino acids in older adults with knee osteoarthritis undergoing total knee arthroplasty.

Study design: Multi-center, randomized, controlled trial with an intervention and a control group.

Study population: 40 older adults (60 - 80 years) with osteoarthritis of the knee undergoing total knee replacement.

Intervention: Controlled vegan diet versus controlled omnivorous diet, for a duration of 14 days.

Main study parameters/endpoints: Primary study parameters are protein synthesis rates of Hoffa's fat pad, synovium, tendon, bone, ligament, menisci, and cartilage. Secondary parameters include blood pressure and plasma amino acids.

Condition or Disease Intervention/Treatment Phase
  • Dietary Supplement: Vegan diet
  • Dietary Supplement: Omnivorous diet
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
40 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
The Effect of a 2-week Preoperative Vegan Diet Versus Omnivorous Diet on the Protein Turnover in the Osteoarthritic Knee
Anticipated Study Start Date :
Mar 1, 2024
Anticipated Primary Completion Date :
Feb 28, 2025
Anticipated Study Completion Date :
Feb 28, 2025

Arms and Interventions

Arm Intervention/Treatment
Experimental: Vegan group

Subjects in the vegan group will receive a vegan diet during the 2-week preoperative period.

Dietary Supplement: Vegan diet
Vegan diet for 2 weeks before surgery

Active Comparator: Omnivorous group

Subjects in the omnivorous group will receive an omnivorous diet during the 2-week preoperative period.

Dietary Supplement: Omnivorous diet
Omnivorous diet for 2 weeks before surgery

Outcome Measures

Primary Outcome Measures

  1. Change in tissue-specific protein synthesis rates [During the 2-week preoperative period]

    Tissue-specific protein synthesis rates in the knee using D2O dosing methodology

Secondary Outcome Measures

  1. Change in blood pressure [Measured at baseline and 1 day before surgery]

    Blood pressure measurement using an CE-certified ambulatory blood pressure monitor

  2. Change in plasma amino acids [During the 2-week preoperative period]

    Difference in circulating concentrations between the two diets. In addition, it will be investigated if plasma amino acids can be used as a marker for dietary intake.

Eligibility Criteria

Criteria

Ages Eligible for Study:
60 Years to 80 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Written informed consent;

  • Patients scheduled for total knee arthroplasty;

  • BMI between 20-32 kg/m2;

  • Aged 60 - 80 years;

  • Mentally competent, as judged by the treating physician;

Exclusion Criteria:
  • Following a vegetarian or vegan diet or a diet that affects protein intake during the six months prior to the study;

  • Participating in a structured exercise training program in the past three months;

  • Lost more than 4 kg body weight during three months prior to the study;

  • Chronic use of medications that affect protein metabolism (i.e. systemic corticosteroids, or prescription strength acne medications);

  • Being diagnosed with one of the following: diabetes mellitus, rheumatoid arthritis, peripheral artery disease Fontaine III or IV, COPD GOLD III or IV, neoadjuvant chemotherapy or radiotherapy, phenylketonuria, collagen disorders (e.g. Marfan and Ehler-Danlos);

  • Alcohol abuse;

  • Surgical intervention to the knee in the past four weeks;

  • Total parenteral nutrition at day of surgery;

  • Glomerular filtration rate (GFR) <20 mL/min/1.73 m2;

  • Allergic or intolerant to any product included in the diets;

  • Osteoarthritis of the knee secondary to septic arthritis, osteonecrosis, fracture, osteochondritis dissecans, or malignant processes;

  • Any other medical condition that may interfere with the safety of the participants or the outcome parameters, in the investigators judgement;

  • Not willing to stop nutritional supplements, with the exception of vitamin D and supplements on medical advice.

  • Investigator's uncertainty about the willingness or ability of the participant to comply with the protocol instructions;

  • Participation in other studies that may have an impact on the outcomes during the three months before the start of the current study.

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Wageningen University
  • Gelderse Vallei Hospital
  • Rijnstate Hospital

Investigators

  • Principal Investigator: Lisette de Groot, PhD, Wageningen University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Lisette de Groot, prof.dr.ir., Wageningen University
ClinicalTrials.gov Identifier:
NCT06130956
Other Study ID Numbers:
  • 2022023
First Posted:
Nov 14, 2023
Last Update Posted:
Nov 14, 2023
Last Verified:
Nov 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Nov 14, 2023